CD33.t-haNK

N/A

Report date: 2021/12/24 10:29:12

Base Information

Drug NameCD33.t-haNK

Drug Alias NameCD33.t-haNK

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionAnti-Myeloid cell surface antigen CD33

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsHead and Neck Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmunitybio Inc Nantkwest Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmunitybio Inc Nantkwest Inc

Inactive CompaniesN/A

Active IndicationsHead and Neck Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A